Annual report pursuant to Section 13 and 15(d)

Convertible Promissory Note Receivable

v3.21.2
Convertible Promissory Note Receivable
12 Months Ended
Jun. 30, 2021
Convertible Promissory Note Receivable [Abstract]  
Convertible Promissory Note Receivable

6. Convertible Promissory Note Receivable

On October 1, 2020, the Company entered into a master services agreement with Safi Biosolutions, Inc. (“Safi”). In addition, the Company invested $1.5 million in Safi in the form of a convertible promissory note (the "Note"). The Note bears interest at the rate of 5% per annum and is convertible into shares of Safi’s common stock (as defined). Principal and accrued interest mature on October 1, 2023.  For Fiscal 2021, interest income amounted to $56,000. As of June 30, 2021, the Note balance and accrued interest totaled $1,556,000.